SWAV - Shockwave Medical Inc Stock Price, Fair Value and News

327.50USD0.00 (0.00%)Market Closed

Market Summary

USD327.500.00

Market Closed

0.00%

SWAV Alerts

2 major insider sales recently.

SWAV Stock Price

View Fullscreen

SWAV RSI Chart

SWAV Valuation

Market Cap

12.2B

Price/Earnings (Trailing)

83.16

Price/Sales (Trailing)

16.77

EV/EBITDA

66.05

Price/Free Cashflow

74.02

SWAV Price/Sales (Trailing)

SWAV Profitability

EBT Margin

23.87%

Return on Equity

22.03%

Return on Assets

9.4%

Free Cashflow Yield

1.35%

SWAV Fundamentals

SWAV Revenue

Revenue (TTM)

730.2M

Rev. Growth (Yr)

40.93%

Rev. Growth (Qtr)

9.12%

SWAV Earnings

Earnings (TTM)

147.3M

Earnings Growth (Yr)

-68.56%

Earnings Growth (Qtr)

26.64%

Breaking Down SWAV Revenue

Last 7 days

0.1%

Last 30 days

19.5%

Last 90 days

49.7%

Trailing 12 Months

22.7%

How does SWAV drawdown profile look like?

SWAV Financial Health

Current Ratio

11.76

Debt/Equity

1.09

Debt/Cashflow

0.27

SWAV Investor Care

Shares Dilution (1Y)

2.47%

Diluted EPS (TTM)

3.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	557.2M	616.6M	671.3M	730.2M
2022	298.9M	363.7M	429.9M	489.7M
2021	84.5M	130.1M	175.7M	237.1M
2020	50.9M	51.1M	59.4M	67.8M
2019	18.2M	25.9M	33.7M	42.9M
2018	4.4M	7.0M	9.6M	12.3M
2017	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Shockwave Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	francis laura	sold	-450,000	300	-1,500	-
Mar 26, 2024	francis laura	acquired	9,882	6.588	1,500	-
Mar 26, 2024	zacharias isaac	sold	-1,150,680	287	-4,000	president, cco
Mar 26, 2024	francis laura	gifted	-	-	1,500	-
Mar 26, 2024	francis laura	gifted	-	-	-1,500	-
Mar 11, 2024	zacharias isaac	sold (taxes)	-138,633	250	-554	president, cco
Mar 06, 2024	phung trinh	sold	-5,315	253	-21.00	vp, finance
Mar 06, 2024	watkins frank t	acquired	6,832	3.416	2,000	-
Mar 06, 2024	watkins frank t	sold	-507,294	253	-2,000	-
Mar 04, 2024	phung trinh	sold (taxes)	-8,703	263	-33.00	vp, finance

Which funds bought or sold SWAV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Artemis Investment Management LLP	new	-	28,130,000	28,130,000	0.36%
Apr 16, 2024	Independence Bank of Kentucky	unchanged	-	2,026	4,884	-%
Apr 16, 2024	Alliance Wealth Advisors, LLC	new	-	295,672	295,672	0.19%
Apr 16, 2024	OneAscent Wealth Management LLC	new	-	217,000	217,000	0.08%
Apr 16, 2024	Perpetual Ltd	new	-	521,659	521,659	-%
Apr 16, 2024	Robbins Farley	added	33.29	1,105,840	1,971,360	1.04%
Apr 16, 2024	Financial Management Professionals, Inc.	unchanged	-	41,000	99,000	0.01%
Apr 16, 2024	Arlington Trust Co LLC	sold off	-100	-953	-	-%
Apr 16, 2024	Trifecta Capital Advisors, LLC	unchanged	-	27,014	65,126	0.02%
Apr 16, 2024	OneAscent Financial Services LLC	new	-	247,000	247,000	0.03%

Are Funds Buying or Selling SWAV?

Are funds buying SWAV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SWAV

No. of Funds

SWAV Alerts

2 major insider sales recently.

Unveiling Shockwave Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.85%	3,633,720	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	6.78%	2,500,594	SC 13G
Jan 24, 2024	blackrock inc.	10.1%	3,740,596	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	2.8%	1,012,393	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jan 23, 2023	blackrock inc.	12.7%	4,572,659	SC 13G/A
Jan 10, 2023	vanguard group inc	10.22%	3,694,931	SC 13G/A
Jul 08, 2022	blackrock inc.	12.1%	4,313,553	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	8.7%	3,077,252	SC 13G/A

Recent SEC filings of Shockwave Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 05, 2024	DFAN14A	DFAN14A
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 26, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Shockwave Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.40%	4.53%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.42%	-9.87%	53.41	3.44	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.35	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.34	3.18	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

Shockwave Medical Inc News

Latest updates

Shockwave Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.1%	203	186	180	161	144	131	121	94.00	84.00	65.00	56.00	32.00	23.00	20.00	10.00	15.00	14.00	11.00	10.00	7.00	5.00
Gross Profit	10.0%	178	162	156	140	127	113	104	81.00	72.00	54.00	46.00	24.00	16.00	14.00	7.00	10.00	9.00	7.00	6.00	4.00	-
Costs and Expenses	14.0%	134	118	123	100	84.00	77.00	74.00	65.00	58.00	51.00	46.00	41.00	32.00	27.00	25.00	29.00	13.00	24.00	21.00	19.00	9.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.00	25.00	29.00	-	20.00	17.00	16.00	-
S&GA Expenses	18.1%	67.00	57.00	57.00	54.00	43.00	42.00	41.00	36.00	33.00	28.00	26.00	24.00	16.00	14.00	11.00	10.00	10.00	8.00	7.00	6.00	5.00
R&D Expenses	7.1%	42.00	40.00	37.00	27.00	24.00	20.00	21.00	17.00	15.00	14.00	12.00	10.00	9.00	8.00	8.00	12.00	10.00	8.00	7.00	7.00	6.00
EBITDA Margin	-0.6%	0.26*	0.26*	0.26*	0.28*	0.26*	0.22*	0.17*	0.11*	-0.02*	-0.19*	-0.38*	-0.79*	-	-	-	-	-	-	-	-	-
Interest Expenses	17.6%	3.00	3.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	10.7%	11.00	10.00	4.00	2.00	-96.26	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings Before Taxes	23.0%	55.00	45.00	33.00	41.00	45.00	35.00	26.00	15.00	13.00	2.00	-0.35	-23.56	-15.87	-12.90	-18.10	-18.75	-14.73	-12.93	-10.59	-12.79	-11.21
EBT Margin	-2.0%	0.24*	0.24*	0.25*	0.26*	0.25*	0.21*	0.15*	0.10*	-0.04*	-0.21*	-0.40*	-0.83*	-	-	-	-	-	-	-	-	-
Net Income	26.6%	44.00	35.00	29.00	39.00	141	35.00	26.00	15.00	13.00	2.00	-0.42	-23.60	-15.87	-12.93	-18.12	-18.77	-14.74	-12.96	-10.61	-12.80	-11.22
Net Income Margin	-44.5%	0.20*	0.36*	0.40*	0.43*	0.44*	0.20*	0.15*	0.10*	-0.04*	-0.22*	-0.41*	-0.83*	-	-	-	-	-	-	-	-	-
Free Cashflow	44.1%	64.00	44.00	31.00	27.00	41.00	27.00	25.00	-1.35	18.00	6.00	-0.52	-21.35	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	6.3%	1,567	1,474	787	783	646	476	417	373	346	299	276	269	272	281	287	221	232	138	147	158	53.00
Current Assets	8.6%	1,225	1,129	456	591	459	395	352	310	286	256	240	233	246	258	264	198	217	131	141	152	49.00
Cash Equivalents	-34.1%	328	498	141	281	157	128	100	66.00	91.00	93.00	86.00	58.00	52.00	215	218	123	140	39.00	42.00	138	40.00
Inventory	10.7%	108	97.00	92.00	83.00	75.00	69.00	60.00	53.00	43.00	39.00	36.00	34.00	30.00	29.00	23.00	16.00	12.00	9.00	8.00	7.00	5.00
Net PPE	11.1%	69.00	62.00	60.00	54.00	48.00	39.00	32.00	28.00	24.00	23.00	21.00	20.00	16.00	13.00	13.00	13.00	5.00	4.00	3.00	3.00	3.00
Goodwill	-0.6%	40.00	40.00	40.00	40.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	2.9%	898	873	170	213	135	120	112	105	104	79.00	68.00	65.00	46.00	44.00	42.00	43.00	39.00	30.00	27.00	28.00	23.00
Current Liabilities	33.2%	104	78.00	80.00	142	63.00	54.00	66.00	51.00	52.00	40.00	36.00	33.00	26.00	21.00	18.00	19.00	24.00	19.00	15.00	15.00	9.00
Long Term Debt	0.1%	732	731	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	6.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.1%	732	731	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	11.2%	669	601	617	571	511	356	305	268	242	220	208	204	226	237	245	178	193	108	119	129	-
Retained Earnings	67.0%	110	66.00	31.00	2.00	-36.81	-177	-212	-238	-252	-265	-267	-267	-243	-227	-214	-196	-177	-163	-150	-139	-126
Additional Paid-In Capital	4.2%	558	535	586	569	549	535	519	507	495	486	476	471	469	465	460	374	371	271	270	269	4.00
Shares Outstanding	0.5%	37.00	37.00	37.00	36.00	36.00	36.00	36.00	36.00	35.00	-	34,914	34,797	-	-	-	-	-	-	-	-	-
Float	-	-	-	7,700	-	-	-	-	-	-	-	3,700	-	-	-	4,200	-	-	-	1,000	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	41.6%	71,703	50,651	39,737	33,962	52,436	34,488	28,871	1,937	20,831	9,322	2,186	-17,303	-12,399	-16,430	-18,166	-24,189	-12,570	-10,604	-10,518	-14,415	-9,814
Share Based Compensation	18.5%	21,811	18,410	17,046	15,967	12,643	11,732	11,005	9,510	8,208	7,387	6,523	5,139	3,242	2,846	2,391	1,871	1,310	1,106	818	412	423
Cashflow From Investing	20.8%	-242,262	-305,879	-83,768	6,182	-35,276	-5,276	5,816	-27,414	-23,102	-4,782	27,214	27,086	-153,607	12,106	29,703	4,325	16,791	7,641	-83,555	-420	-851
Cashflow From Financing	-100.0%	-164	612,997	-95,841	83,409	9,596	383	500	2,520	500	2,387	-2,138	-3,200	1,173	1,284	83,648	3,930	96,372	491	-2,067	113,256	19,320

SWAV Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Product revenue	$ 730,230,000	$ 489,733,000	$ 237,146,000
Cost of revenue:
Cost of product revenue	95,388,000	64,996,000	41,438,000
Gross profit	634,842,000	424,737,000	195,708,000
Operating expenses:
Research and development	145,647,000	81,679,000	50,544,000
Sales and marketing	234,837,000	161,995,000	111,288,000
General and administrative	95,265,000	56,929,000	34,747,000
Total operating expenses	475,749,000	300,603,000	196,579,000
Income (loss) from operations	159,093,000	124,134,000	(871,000)
Loss from equity method investment	(1,869,000)	(2,475,000)	(6,286,000)
Interest expense	(6,905,000)	(1,886,000)	(1,096,000)
Other income (expense), net	23,962,000	1,055,000	(582,000)
Net income (loss) before taxes	174,281,000	120,828,000	(8,835,000)
Income tax (benefit) provision	27,003,000	(95,168,000)	301,000
Net income (loss)	147,278,000	215,996,000	(9,136,000)
Other comprehensive income (loss)
Unrealized gain (loss) on available-for-sale securities, net of tax	1,165,000	(659,000)	(211,000)
Adjustment for net gain realized and included in other income, net	(5,000)	(6,000)	0
Total comprehensive income (loss)	$ 148,438,000	$ 215,331,000	$ (9,347,000)
Net income (loss) per share
Basic (USD per share)	$ 4.01	$ 6.02	$ (0.26)
Diluted (USD per share)	$ 3.85	$ 5.70	$ (0.26)
Denominator:
Basic (in shares)	36,706,060	35,900,738	35,098,130
Diluted (in shares)	38,206,269	37,881,590	35,098,130
Revenue, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]	Product [Member]
Cost, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]	Product [Member]

SWAV Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 328,422	$ 156,586
Short-term investments	662,132	147,907
Accounts receivable, net	114,552	71,366
Inventory	107,587	75,112
Prepaid expenses and other current assets	12,567	8,292
Total current assets	1,225,260	459,263
Operating lease right-of-use assets	29,707	32,365
Property and equipment, net	68,923	48,152
Equity method investment	1,643	3,512
Intangible assets, net	92,857	0
Goodwill	39,568	0
Deferred tax assets	99,169	97,568
Other assets	9,436	5,229
TOTAL ASSETS	1,566,563	646,089
CURRENT LIABILITIES:
Accounts payable	8,868	6,721
Accrued liabilities	91,696	55,375
Lease liability, current portion	3,641	1,278
Total current liabilities	104,205	63,374
Lease liability, noncurrent portion	35,103	34,928
Convertible Debt, Noncurrent	731,863	0
Debt, noncurrent portion	0	24,198
Related party contract liability, noncurrent portion	12,273	12,273
Deferred tax liabilities	3,609	0
Long-term income tax liability	1,526	0
Other liabilities	9,307	0
TOTAL LIABILITIES	897,886	134,773
Commitments and contingencies (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; No shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value per share; 281,274,838 shares authorized; 36,990,700 and 36,235,546 issued and outstanding as of December 31, 2023 and 2022, respectively	37	36
Additional paid-in capital	557,882	548,960
Accumulated other comprehensive income (loss)	293	(867)
Retained earnings (accumulated deficit)	110,465	(36,813)
TOTAL STOCKHOLDERS’ EQUITY	668,677	511,316
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 1,566,563	$ 646,089

About Shockwave Medical Inc

ShockWave Medical, Inc., a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

CEO	Mr. Douglas E. Godshall M.B.A.
WEBSITE	https://shockwavemedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1001

Shockwave Medical Inc Frequently Asked Questions

What is the ticker symbol for Shockwave Medical Inc? What does SWAV stand for in stocks?

SWAV is the stock ticker symbol of Shockwave Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Shockwave Medical Inc (SWAV)?

As of Tue Apr 16 2024, market cap of Shockwave Medical Inc is 12.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SWAV stock?

You can check SWAV's fair value in chart for subscribers.

What is the fair value of SWAV stock?

You can check SWAV's fair value in chart for subscribers. The fair value of Shockwave Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Shockwave Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SWAV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Shockwave Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SWAV is over valued or under valued. Whether Shockwave Medical Inc is cheap or expensive depends on the assumptions which impact Shockwave Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SWAV.

What is Shockwave Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, SWAV's PE ratio (Price to Earnings) is 83.16 and Price to Sales (PS) ratio is 16.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SWAV PE ratio will change depending on the future growth rate expectations of investors.